Loading...
The University of Chicago Header Logo
Keywords
Last Name
Institution

Ulcerative Colitis Remission Status After Induction With Mesalazine Predicts Maintenance Outcomes: the MOMENTUM Trial.

Rubin DT, Bradette M, Gabalec L, Dobru D, Márquez J, Inglis S, Magee E, Solomon D, D'Haens G. Ulcerative Colitis Remission Status After Induction With Mesalazine Predicts Maintenance Outcomes: the MOMENTUM Trial. J Crohns Colitis. 2016 Aug; 10(8):925-33.

View in: PubMed

collapse authors with profiles